Tesaro’s Niraparib Takes PARP Inhibitor Lead In Ovarian Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Tesaro Inc. announced the launch of a Phase III trial for its PARP inhibitor niraparib in ovarian cancer, while registrational data from three global Phase III studies for anti-emetic rolapitant are due by the end of 2013.
You may also be interested in...
AstraZeneca Back In The PARP Mix With Olaparib In Ovarian Cancer
Olaparib is off the shelf and into a Phase III trial against ovarian cancer in platinum-sensitive BRCA-positive patients, adding to the list of late-stage PARP inhibitors vying for first-in-class status.
AstraZeneca Back In The PARP Mix With Olaparib In Ovarian Cancer
Olaparib is off the shelf and into a Phase III trial against ovarian cancer in platinum-sensitive BRCA-positive patients, adding to the list of late-stage PARP inhibitors vying for first-in-class status.
Flush With Cash, Tesaro Advances Rolapitant Toward NDA
Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: